The Antibody Society

the official website of the antibody society

An international non-profit supporting antibody-related research and development.

  • LOG IN
  • BECOME A MEMBER
  • About Us
    • Our Team
      • Directors and Officers
      • Our Staff
      • Our Committees
    • Sponsors & Partners
  • Events Calendar
    • Current Events
  • AIRR Community
    • AIRR Community News
    • AIRR Community Newsletter
    • AIRR Community Seminar Series
    • AIRR Community Meetings
      • AIRR Community Meeting VIII – Decoding and Recoding Immunity
      • Zooming into the Community III
      • AIRR Community Meeting VII – Learnings and Perspectives
      • AIRR Community Special Event 2023  – Zooming in to the Community II
      • AIRR Community Meeting VI: “Exploring New Frontiers”
      • AIRR Community Meeting V: “Zooming in to the AIRR Community”
      • AIRR Community Meeting V Pre-Meetings
        • AIRR-seq in the Pandemic
        • AIRR-seq Biological Standards and Workflows
      • AIRR Community Special Event: “Response to COVID-19”
      • AIRR Community Meeting IV: “Bridging the Gaps”
      • AIRR Community Meeting III
        • Day 1
        • Day 2
        • Day 3
        • Day 4
      • AIRR Community Meeting II
      • AIRR Community Meeting I
    • On AIRR – An AIRR Community Podcast
    • AIRR Data Commons
    • AIRR-C Germline Database Resources
    • AIRR Community Publications
    • AIRR Community Working Groups
      • Biological Resources Working Group
      • Common Repository Working Group
      • Diagnostics Working Group
      • Germline Database Working Group
      • Legal and Ethics Working Group
      • Software Working Group
      • Standards Working Group
    • AIRR Community Sub-Committees
      • Communications Sub-Committee
      • Executive Sub-Committee
      • Inferred Allele Review Committee
      • Meetings Sub-Committee
      • Strategic Planning Sub-Committee
    • AIRR Community Webinar Series
    • AIRR Community Calendar
    • AIRR Community Resources
  • Programs
    • Conferences
    • Competitions
      • Huston Award
        • Huston Award submission guidelines
      • Research Competition
      • Science Writing
    • Podcast
    • Webinars
  • Business Intelligence
    • Antibody Discovery & Development
      • Antibody Validation
      • Commercializing Antibody Therapeutics
      • Adaptive Immune Receptor Repertoires
    • Antibody News
    • Antibody therapeutics approved or in regulatory review in the EU or US
      • Antibody therapeutics product data
    • Antibodies to Watch
      • Antibodies in early-stage studies
    • Presentations
  • Learning and Career Center
    • Research Resources
      • Antibodies in late-stage clinical studies
    • Education Resources
    • Society Publications
    • Career Shorts
  • Members
    • Login
    • Note to members
    • Member discount codes
  • Sponsors & Partners
You are here: Home / About Us / Our Team / Directors and Officers / Dennis Burton, Ph.D.

Dennis Burton, Ph.D.

Dennis-BurtonDennis Burton is the Chairman, and Professor in the Department of Immunology and Microbial Science, The Scripps Research Institute, La Jolla, USA. He was recently awarded the James and Jessie Minor Chair in Immunology. He received his B.A. in Chemistry from Oxford University and his Ph.D from Lund University, Sweden in physical biochemistry. He is the Scientific Director of the International AIDS Vaccine Initiative (IAVI) Neutralizing Antibody Consortium and Neutralizing Antibody Center, Director of The Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery (CHAVI-ID) at Scripps, and a member of the Ragon Institute of MGH, MIT and Harvard, Boston, USA. He has held many research grants from the NIH and has published more than 350 papers in scientific journals. He has received numerous awards including the Jenner Fellowship of the Lister Institute and a Fellowship in the American Academy of Microbiology. His research is focused on infectious disease, in particular the interplay of antibodies and highly mutable viruses, notably HIV. He is interested in the potential of broadly neutralizing antibodies to inform vaccine design.

  • Home
  • Privacy & Terms of Use
  • About
  • Directors and Officers
  • Advisors
  • Sponsors & Partners Old
  • Mission & Activities
  • Join the Society
  • Membership Levels
  • Members
  • Login
  • Antibody therapeutics approved or in regulatory review in the EU or US
  • Meeting reports
  • Presentations
  • Contact

©2015 - scicomvisuals